DESIGN OF ORALLY ADMINISTERED PROBIOTIC FORMULATION FOR THE PREVENTION OF OBESITY IN CHILDREN
Castro E., Asenjo S., Bustos A., Bórquez R., González M., Durán D.
Departamento de Bioquímica Clínica e Inmunología, Facultad de Farmacia, Universidad de Concepcion, Chile
Obesity corresponds to an intake/output energy imbalance, but also is influenced by genetic, physiological, metabolic, social and cultural factors. It was recently reported that the microbiota that colonizes the human gut may play an important role in the development of obesity. This study summarizes research in the development of a new oral anti-obesity formulation based on a probiotic strain isolated from breast milk.
Was evaluated the effect of diet supplementation with L. salivarius LPLM-01 strain in a murine diet-induced model of obesity and in a clinical study with schoolchild. Murine model: Mice were randomized. One group feeding with D12450H diet (Low fat diet; LFD) and the second group feeding an isocaloric diet D12451 (High fat diet: HFD). After three months was observed a significant weight increase in the HFD-fed mice versus LFD-fed mice (>30% weight). Then, each group was newly randomized. One subgroup started a diet supplementation with placebo (fruit jelly; LFD-placebo and HFD-placebo). The other subgroup started a diet supplementation with fruit jelly containing 1x109 CFU/g Lactobacillus salivarius LPLM-O1 (LFD-Lac and HFD-Lac). Animal weight was assessed weekly. At the end of the study, the animals were sacrificed and plasma triglycerides (TG), total cholesterol (TC), plasma alanine aminotransferase, aspartate aminotransferase, blood glucose, insulin, leptin and Interleukin 6 were measured. Clinical study: A randomized, placebo controlled study was conducted, in which patients with higher BMI (obese or overweight) were compared to patients with normal BMI. Patients of both weight conditions receive fruit jelly containing 1x109 CFU/g Lactobacillus salivarius LPLM-O1 strain or placebo for a period of four weeks. Assessment of body composition parameters, biochemical and immunological measures and fecal bacteria in stool was performed at baseline and at week 8.
Supplementing the diet with the strain LPLM-O1 does not significantly modify glucose tolerance or insulin response, but it did reduce body weight gain in both diet group when compared to the placebo (p<0.05). Weight loss was related to a reduction of BMI, fasting glucose, insulinemia, and subcutaneous and periovarian adipose tissues, without being statistically significant. However, weight loss was also related to a significant reduction of leptinemia in the HFD+LPLM-O1 group., in comparison with the placebo group (p<0.05). Clinical study showed that the application of the probiotic strain is safety in children, no significant differences in body composition and metabolic markers were observed. But important tendencies were shown.
Discussion. LPLM-O1 diet supplementation reduces adipose tissue mass associated with decreased adipocyte size in obese mice. Altogether, diet supplementation with probiotic strain improves obesity markers in a murine diet-induced obesity model. Even a discrete effect on glucose tolerance and insulin sensitivity, diet supplementation with LPLM-O1 strain reduces total weight in obese mice associated with an improvement in inflammatory markers and reduced circulating basal glucose and insulin levels compared to lean-mice. Clinically, no significant differences were observed, however the probiotic diet could have impact decreasing BMI, glycemia and High Sensitive C reactive protein (PCRhs). The probiotic oral formulation is now in patenting process.
Keywords: Probiotic, Obesity, Lactobacillus, Children, Prevention
Castro E., et al. (2016). Design of orally administered probiotic formulation for the prevention of obesity in children. Conference Proceedings of IPC2016. Paper presented at the International Scientific Conference on Probiotics and Prebiotics, Budapest (p. 17.). IPC2016